3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
134
Gemcitabine
101
Paclitaxel
100
Carboplatin
85
Nivolumab
66
Docetaxel
62
Bevacizumab
62
Cisplatin
58
Pemetrexed
51
Fluorouracil
49
Cyclophosphamide
41
Cetuximab
41
trametinib
38
venetoclax
37
Leucovorin
37
Irinotecan
37
Sorafenib
35
Capecitabine
35
Ipilimumab
33
Dexamethasone
32
atezolizumab
31
Erlotinib Hydrochloride
28
130-nm albumin-bound paclitaxel
28
Drug Therapy
27
Epoetin Alfa
26
Doxorubicin
25
Oxaliplatin
24
Albumin-Bound Paclitaxel
24
Prednisone
23
Rituximab
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled